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Intraneuronal depositions of α-synuclein have been implicated in the pathogenesis of Parkinsons’s disease (PD). Previous reports
haveidentiﬁedthecrosslinkingbetween α-synuclein andtTG(tissuetransglutaminase)inboth PDpatientsandthecellularmodel.
However, no researches have been conducted to further investigate their interaction in physiological conditions. To address this
question, we generated the SH-SY5Y cell line which stably expressed the wild-type or mutant (Ser129Ala) α-synuclein. After
the treatment with okadaic acid, α-synuclein started forming aggregates upon the activation of tTG. Coimmunoprecipitation
assaysrevealed a decreased interaction of the mutant α-synuclein S129A with tTG compared with the wild-type α-synuclein. Cells
expressing the wild-type α-synuclein showed increased eosinophilic cytoplasmic inclusion bodies that resembled Lewy bodies
compared with the mutant.Double immunoﬂuorescencestainingconﬁrmedthe colocalizationofthe phosphorylated α-synuclein
and the tTG in the cells. The S129A mutant demonstrated a lesser degree of colocalization than the wild type.
1.Introduction
Parkinson’s disease (PD) is a common neurodegenerative
disorder. Hallmarks of PD are the degeneration of dopamin-
ergic neurons in the substantia nigra pars compacta (SNpc)
and the presence of cytoplasmic inclusions known as Lewy
bodies (LBs) in surviving neurons [1]. Although it is still
under debate whether α-synuclein, the major component of
Lewy bodies, plays a key role in the death of dopamine neu-
rons, there is growing evidence suggesting its involvement in
PD pathogenesis [2]. The well-accepted hypothesis proposes
that the functional α-synuclein undergoes conformational
change in pathological conditions which prevents the degra-
dation of the abnormal proteins. As a consequence, these
abnormal proteins aggregate to form cytotoxic Lewy bodies
[3].
It has been shown that there is increased serine phos-
phorylation at SNpc in both familial and sporadic PD
patients. Four serine phosphorylation sites have been
identiﬁed in α-synuclein, Ser9, Ser42, Ser87, and Ser129.
Ser129 is the most common one. Neurotoxic agents
such as paraquat, and rotenone, 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) can cause serine
phosphorylation of α-synuclein at position 129 [4]. Further
studies showed that serine phosphorylation at position
129 promoted the formation of a-synuclein aggregates in
the cytoplasm [5] .D e s p i t et h ea b o v ee v i d e n c e ,t h e r ea r e
reports demonstrating no alteration or even the prevention
of a-synuclein aggregation after phosphorylation [6, 7]. The
controversy might be explained by the diﬀerent models used
in the investigations, for example, some agents may function
as the catalyzer or the crosslinker to enhance the aggregation
of the α-synuclein.2 ISRN Neurology
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Figure 1: Stable expression of the wild and mutant α-synuclein
in vitro. Immunoblots of α-synuclein and β-actin in SH-SY5Y
cells without transfection (Lane 1), transfected with empty vector
(Lane 2), or vectors encoding the wild-type (Lane 3) or mutant
(Lane4)α-synuclein. Celllysates were analyzedby immunoblotting
using anti-α-synuclein antibody. β- a c t i nw a su s e da sal o a d i n g
control. The wild-type α-synuclein and the S129A α-synuclein
protein in transfection groups were obviously higher than that in
nontransfected and empty plasmid transfected groups.
Tissue transglutaminase (tTG) is a key member of trans-
glutaminases family. It is predominantly expressed in the
central nervous system and has functions in neural develop-
ment, neural regeneration, and others [8, 9]. tTG mediates
the posttranslational modiﬁcation of proteins including the
crosslinking and the polypeptide formation. This reaction is
calcium dependent and inhibited by guanosine triphosphte
(GTP) [10, 11].tTG inducestheprotein-protein crosslinking
via transaminations, the formation of amide bonds between
the glutamine side chains and the ε-amino groups of lysine
residues [12, 13]. It is proposed that the protein-protein
crosslinking catalyzed by the tTG plays a causative role in
various neurodegenerative diseases [14]. The crosslinking
between α-synuclein and tTG had been reported in PD
patients and the cellular models that were cotransfected with
α-synuclein and tTG. Further investigations are needed to
addresstheirparticipationincellphysiology,alongwiththeir
interaction in pathophysiology.
In this study, we investigated the role of serine 129
phosphorylation of α-synuclein in the formation of eos-
inophilic cytoplasmic inclusions in vitro. The mutant α-
synuclein S129A showed signiﬁcantly reduced cytoplasmic
eosinophilic inclusion bodies compared with the wild-type
α-synuclein. When α-synuclein is immunocoprecipited with
the tTG, the mutant presented with decreased protein
aggregation. We also discoveredthat thetTG phosphorylated
α-synuclein at Ser129 and activated the aggregation of the
abnormal proteins to form inclusion bodies. Our results
strongly supported the involvement of the α-synuclein in PD
pathogenesis.
2.Materialand Methods
2.1. Chemicals and Reagents. Cell culture media, Lipo-
fectAMINE Plus reagent, and Agarose beads were pur-
chased from Invitrogen (Carlsbad, CA). Anti-α-synuclein
monoclonal antibody was from BD Biosciences (PaloAlto,
CA), antiphospho-S129 α-synuclein monoclonal antibody
was from Woko (Osaka, Japan), antitissue transglutam-
inase polyclonal antibody was from Abcam (London,
UK), antitissue transglutaminase monoclonal antibody was
from Thermo (Thermo, USA), horseradish peroxidase-
(HRP-) conjugated β-actin was from kangchen (Shanghai,
China), Cyanine 3- (Cy3-) conjugated goat antimouse IgG,
ﬂuorescein- (FITC-) conjugated goat antirabbit IgG, and all-
trans retinoicacidandmonodactylacidwerefromSigma(St.
Louis, MO, USA). Okadaic acid was from Alexis (Plymouth,
USA), HE staining kit was from Applygen (Beijing, China),
G418 was from GIBCO (Grand Island, USA), and HRP-
conjugated antimouse and antirabbit secondary antibodies
were purchased from Boster (Wuhan, China).
2.2. Plasmid Construction, Site-Directed Mutagenesis, and
Transfection. The wild-type α-synuclein expressing plasmid
was a generous gift from Dr. Raohua Li. The Quickchange
Lighting Site-Directed Mutagenesis Kit was used to generate
the mutant S129A following the manufactory protocol. The
wild type and the mutant were conﬁrmed by the sequencing.
The pcDNA3.1(+)/α-ynucleinorthe pcDNA3.1(+)/S129Aα-
synuclein expressing plasmids were added to lipofectamine
2000 to transfect human neuroblastoma cells SH-SY5Y to
produce their stable expression cell lines. The transfection
was performed following the manufactory’s instruction.
Western blot was conducted to conﬁrm the expression of the
wild-type and the mutant α-synuclein.
2.3. Cell Culture and tTG Production. SH-SY5Y cells were
Cultured in Dulbeeeo’s Modiﬁed Eagle’s Medium (DMEM)
thatwassupplementedwith10%fetalserumand300mg/mL
G418, at 37◦Cw i t h5 %C O 2.T op r o d u c et T Gi nt h es y s t e m ,
cells were cultivated in the above medium for 7 days except
that 2% fetal serum and 20umol/L retinoic acid were added
(Zhang et al., 1998). All experiments were carried out in
subconﬂuent cell cultures.
2.4. Hematoxylin and Eosin Staining, Double Immunoﬂuo-
rescence. Hematoxylin and eosin (H&E) staining was per-
formed following the manufactory instruction. Double
immunoﬂuorescence was conducted as described previ-
ously (Tanaka et al., 2001). In short, cells were washedISRN Neurology 3
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Figure 2:Downregulationofthecolocalizationofthemutantα-synuclein (S129A)andtTG. ImmunoﬂuorescenceofP129α-synuclein (red)
andtTG(green)inthreecell lines(×400).Cellswere transfected withemptyvectors(a–c),orvectorsencodingthewild-type (d–f)ormutant
(g–i) α-synuclein; cells were double-labeled with antibodies against P129 α-synuclein ((a), (d), (g), Cy3-conjugated) and tTG ((b), (e), (h),
FITC-conjugated) to detect the colocalizationof α-synuclein and tTG. (c, f, i) are merged images (yellow indicates colocation) ofcell bodies;
Cells were incubated in the presence of 20μM retinoic acid (RA) for 7 days, then treated by 20nM okadaic acid for 24h. The mutant S129A
demonstrated the downregulated colocalization compared with the wild-type and the control cells.
with 1 × phosphate-buﬀered saline (PBS), ﬁxed with 4%
paraformaldehyde for 15 min, and permeabilized with 0.2%
TritonX-100for10min,followedbyincubationwiththepri-
mary antibodiesofanti-α-ynuclein(1:100),antitissue trans-
glutaminase (1:100), along with the secondary antibodies
of Cy3-conjugated antimouse (1:200) or FITC-conjugated
antirabbit (1:100) for 2 hours at room temperature. Cells
were analyzed under the ﬂuorescence microscopy (Nikon,
Japan). Fluorescence intensity was measured to access the
formation ofinclusionbodies. The ﬂuorescencepositive cells
were counted in six diﬀerent microscopic ﬁelds with 1000
cells analyzed in each experimental condition.
2.5. Western Blot. Western blot was performed as the fol-
lowing. Cells were washed with ice-cold PBS and lysed with
100μL( RI P Al y s i sb u ﬀer(10%Tris-HCl,20% sodiumdeoxy-
cholate, 10% glycerol) containing protease inhibitors. The
sample was incubated at 4◦C for 30 minutes and followed
by centrifugation at 10,000rpm for 10min. The supernatant
was collected, and the protein concentration was measured
using bicinchoninic acid- (BCA-) 100 Protein Quantitative
Analysis Kit (Shenergy Biocolor BioScicnce & Technology
Company, China). 25μg of the protein sample was loaded
for western blot analysis. After gel electrophoresis, protein
samples were transferred onto a polyvinylidene diﬂuoride4 ISRN Neurology
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Figure 3: Decreased crosslinking between tTG and the mutant α-
synuclein S129A. Cells were transfected with empty vectors, vectors
encoding the wild-type or the mutant α-synuclein S129A. They
were treated with 20μM retinoic acid for 7 days and incubated
for 24h in the presence of 20nM okadaic acid to generate tTG
in the system. Immunoprecipitation was performed to access the
interaction between tTG and α-synuclein. The mutant S129A
showed signiﬁcant reduction in the crosslinking between the tTG
and the α-synuclein monomer and dimer. ∗P<. 01 compared with
cells transfected with empty vectors.
(PVDF) membrane, blocked by 5% nonfat dry milk in 1 ×
Tris buﬀered saline containing 0.1% Tween-20 for 2h, and
incubated with the primary antibodies of anti-α-synuclein
(1:1000), at 4◦C overnight. The membrane was washed and
the incubated with horseradish peroxidase.
(HRP)-conjugated goat antimouse or antirabbit IgG
(1:2000) have been incubated for 1h at room temper-
ature, and developed with an ECL-plus chemilumines-
cencekit for 1–5min and exposed to a X-ﬁlm. To demon-
strate the equal loading of the protein in each lane, the
membranes were stripped (100mM 2-mercaptoethanol,
2%SDS,62.5mMTris–HCl,pH6.7)andreprobedwithHRP-
conjugated β-actin (1:5000 dilution) antibody, followed
by the exposure to an X-ﬁlm. The images were captured
using an Imager gel documentation system, and the band
intensitieswere evaluatedby thedensitometric analysis using
the imager software.
3.StatisticalAnalysis
All results were presented as Mean ± SD based on at least
three independent experiments performed in duplicates.
Overall diﬀerencesamong groups were determined by analy-
sis of variance (ANOVA). A posteriori pairwise diﬀerences
were determined using the Student-Newman-Keuls q-test.
Data were analyzed by SPSS13.0 software. P<. 05 was
considered statistically signiﬁcant.
4.Results
4.1. Generation of the Wild-Type and the Mutant α-Synuclein
(S129A) Expressing Cell Lines. Western blot results showed
that the wild-type α-synuclein and the S129A α-synuclein
protein in transfection groups were obviously higher than
that in nontransfected and empty plasmid transfectied
groups (Figure 1). These suggested that the wild-type α-
synuclein and the mutant S129A α-synuclein were induced
into target cells and expressed successfully.
4.2. Downregulation of the Cytoplasmic Colocalization of
tTG and α-Synuclein in the Mutant S129A. The serine
phosphorylated α-synuclein colocalized with the tTG in the
cytoplasma predominantly. Intranuclear colocalization was
identiﬁed but less common. The mutant S129A demon-
stratedareductionincolocalizationcomparedwiththewild-
type and the control cells (Figure 2).
4.3. Decrease in α-Synuclein-tTG Crosslinks in the Mutant
S129A. Both serine phosphorylated α-synuclein dimers
and monomers interacted with tTGs. After OA treatment,
the mutant S129A demonstrated signiﬁcantly decreased
crosslinks between the α-synuclein and the tTG compared
with the wild type (P<. 01). The crosslinks were reduced to
lower than that of the baseline control cells transfected with
empty vectors (Figure 3).
4.4. Inhibition of Lewy Body-Like Inclusion Body Formation
and Apoptotic Cell Death in the Mutant S129A. H&E stain
showed that 24h posttreatment with OA, there was down-
regulation of eosinophilic inclusion body formation in the
mutant S129A compared with the wild type (P<. 01).
The mutant S129A demonstrated signiﬁcantly decreased
cytoplasmic inclusion body formation compared with the
cells transfected with the wild-type α-synuclein (Figure 4).
5.Discussion
The presence of insoluble Lewy bodies in the brain of
PD patients is the pathological hallmark of the disease. It
has been identiﬁed that the α-synuclein and tTG are the
two major components of the Lewy bodies. Although it
remains inconclusive about the role of α-synuclein in the
pathogenesis of PD, in vitro and in vivo studies have shown
that α-synuclein is a cellular substrate of tTG [15–17]. In a
cell model, cos-7 cells were transfected with the wild-type
α-synuclein plasmid in the absence or presence of tissueISRN Neurology 5
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Figure 4: Reduced cytoplasmic inclusion body formationand apoptotic cell death in the α-synuclein mutant S129A. Cells were transfected
with empty vectors, vectors encoding the wild-type or the mutant α-synuclein S129A. They were treated with 20μM retinoic acid for 7
days followed by incubation in 20nM okadaic acid for 24h (A, B, C). The mutant S129A demonstrated signiﬁcantly decreased cytoplasmic
inclusion body formation compared with the cells transfected with the wild-type α-synuclein.
transglutaminase. Cotransfection with thetTGase expressing
plasmids induced the formation of insoluble α-synuclein
aggregates.TheaggregationwastTGasedosedependent[18].
In this study, we further investigated the interaction between
α-synuclein and tTG in vitro via the upregulation of tTG
using retinoic acid followed by Monodansyl acid addition to
blockitsfurtherproduction[19].Ourresultsshowedthatthe
suppression of the tTG decreased cytoplasmic eosinophilic
inclusion formation when treated with okadaic acid. The
inclusion formation was signiﬁcantly inhibited in the α-
synuclein mutant S129A. Our results indicated that the
crosslinking of α-synuclein and tTG regulated the formation
of cytoplasmic Lewy body-like inclusion bodies.
α-synuclein is modulated by several posttranslational
modiﬁcations [20]. The serine 129 phosphorylation is one of
the most important posttranslational modiﬁcations [21, 22].
It has been reported that serine 129 phosphorylation of α-
synuclein contributes to the development of PD [21, 23].
Several protein kinases, such as CK1, CK2, and a family
of G-protein-coupled receptor kinases (GRKs), have been
found to phosphorylate alpha-synuclein [24, 25]. However,
it is not clear whether serine 129 phosphorylation plays
an essential role in Lewy body formation. It was reported
that the blockage of of serine 129 phosphorylation increased
inclusion formation in α-synuclein transgenic ﬂies [26].
In this study, we investigated the serine phosphorylation
and its regulation of inclusion body formation using a
mammalian cell model. We discovered that the muta-
tion S129A prevented the phosphorylation of α-synuclein,
therfore suppressed its cytoplasmic aggregation (Figure 4).
EarlierstudiesfoundthattheactivationoftTGresultedinthe
formation of insoluble aggregates of wild-type α-synuclein
[22]. However, There were concerns that the ﬁnding might
not be physiologically relevant by the transient expression
of α-synuclein in the investigation. Furthermore, there
is discrepancy that investigations using stable expression
cells found no aggregation of α-synuclein [24, 26]. This
phenomenon might be explained due to the relatively low
expression levelsofα-synuclein in stablecelllines, suggesting
that expression levels of α-synuclein are a critical factor for
the aggregate formation of α-synuclein [27].
6.Conclusions
We demonstrated that Ser129 phosphorylation was required
forthecrosslinkingofα-synucleinandtTG.Theirinteraction
induced the formation of cytoplasmic Lewy body-like inclu-
sion bodies. Our results strongly support that α-synuclein,
tTG, and their interaction contribute to the development of
Parkinson’s disease.6 ISRN Neurology
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